These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 27926776)

  • 1. Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.
    Winder AD; Maniar KP; Wei JJ; Liu D; Scholtens DM; Lurain JR; Schink JC; Buttin BM; Filiaci VL; Lankes HA; Ramirez NC; Park K; Singh M; Lieberman RW; Mannel RS; Powell MA; Backes FJ; Mathews CA; Pearl ML; Secord AA; Peace DJ; Mutch DG; Creasman WT; Kim JJ
    Cancer; 2017 Apr; 123(7):1144-1155. PubMed ID: 27926776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synuclein-γ (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease.
    Strohl A; Mori K; Akers S; Bshara W; Buttin B; Frederick PJ; Helenowski IB; Morrison CD; Odunsi K; Schink JC; Scholtens DM; Wei JJ; Kim JJ
    J Ovarian Res; 2016 Nov; 9(1):75. PubMed ID: 27809878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma.
    Morgan J; Hoekstra AV; Chapman-Davis E; Hardt JL; Kim JJ; Buttin BM
    Gynecol Oncol; 2009 Aug; 114(2):293-8. PubMed ID: 19476987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer.
    Guo J; Shou C; Meng L; Jiang B; Dong B; Yao L; Xie Y; Zhang J; Chen Y; Budman DR; Shi YE
    Int J Cancer; 2007 Sep; 121(6):1296-305. PubMed ID: 17534899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
    Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
    Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?
    Boruta DM; Gehrig PA; Groben PA; Bae-Jump V; Boggess JF; Fowler WC; Van Le L
    Cancer; 2004 Nov; 101(10):2214-21. PubMed ID: 15452833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of synuclein-γ predicts lack of benefit from radiotherapy for breast cancer patients.
    Min L; Zhang C; Ma R; Li X; Yuan H; Li Y; Chen R; Liu C; Guo J; Qu L; Shou C
    BMC Cancer; 2016 Sep; 16(1):717. PubMed ID: 27595752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis.
    Wu K; Quan Z; Weng Z; Li F; Zhang Y; Yao X; Chen Y; Budman D; Goldberg ID; Shi YE
    Breast Cancer Res Treat; 2007 Mar; 101(3):259-67. PubMed ID: 16821081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of γ-synuclein as a stage-specific marker in bladder cancer by immunohistochemistry.
    Zhao J; Xing N
    Med Sci Monit; 2014 Dec; 20():2550-5. PubMed ID: 25479371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study.
    Erickson BK; Najjar O; Damast S; Blakaj A; Tymon-Rosario J; Shahi M; Santin A; Klein M; Dolan M; Cimino-Mathews A; Buza N; Ferriss JS; Stone RL; Khalifa M; Fader AN
    Gynecol Oncol; 2020 Oct; 159(1):17-22. PubMed ID: 32709539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of netrin-1 in uterine serous carcinoma and its association with prognosis.
    Ucuncu Kefeli A; Yaprak Bayrak B; Betul Tunce E; Vural C; Suyusal IH; Kefeli U; Aksu MG
    Int J Gynaecol Obstet; 2024 Sep; 166(3):1337-1344. PubMed ID: 38588254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma.
    Díaz-Montes TP; Ji H; Smith Sehdev AE; Zahurak ML; Kurman RJ; Armstrong DK; Bristow RE
    Gynecol Oncol; 2006 Jan; 100(1):139-44. PubMed ID: 16182348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in Survival of Patients With Uterine Serous Carcinoma From 1988 to 2011: A Population-Based Study.
    Mahdi H; Han X; Moulton L; Vargas R
    Int J Gynecol Cancer; 2017 Jul; 27(6):1155-1164. PubMed ID: 28562471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen.
    Lee LJ; Demaria R; Berkowitz R; Matulonis U; Viswanathan AN
    Gynecol Oncol; 2014 Jan; 132(1):65-9. PubMed ID: 24211401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.
    Hong JC; Foote J; Broadwater G; Gaillard S; Havrilesky LJ; Chino JP
    Int J Gynecol Cancer; 2017 May; 27(4):720-729. PubMed ID: 28375927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 immunohistochemical staining as a prognostic indicator in uterine serous carcinoma.
    Beirne JP; Quinn JE; Maxwell P; Kalloger SE; McAlpine J; Gilks CB; Harley IJ; McCluggage WG
    Int J Gynecol Cancer; 2013 Jan; 23(1):113-8. PubMed ID: 23221734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of γ-Synuclein in Bladder Carcinoma: A Possible Marker for Prognosis.
    Chen Z; Ji Z; Wang Q; Shi B; Shou C; Liu C; Fan H; Li H; Davidson KT; Wakefield MR; Ball TW; Fang Y
    Anticancer Res; 2016 Mar; 36(3):951-6. PubMed ID: 26976983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.
    Santin AD; Bellone S; Siegel ER; Palmieri M; Thomas M; Cannon MJ; Kay HH; Roman JJ; Burnett A; Pecorelli S
    Am J Obstet Gynecol; 2005 Mar; 192(3):813-8. PubMed ID: 15746676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of management on the prognosis of pure uterine papillary serous cancer - a Taiwanese Gynecologic Oncology Group (TGOG) study.
    Huang CY; Tang YH; Chiang YC; Wang KL; Fu HC; Ke YM; Lau HY; Hsu KF; Wu CH; Cheng WF
    Gynecol Oncol; 2014 May; 133(2):221-8. PubMed ID: 24556064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor suppressor gene, cell surface adhesion molecule, and multidrug resistance in Müllerian serous carcinomas: clinical divergence without immunophenotypic differences.
    Soslow RA; Slomovitz BM; Saqi A; Baergen RN; Caputo TA
    Gynecol Oncol; 2000 Dec; 79(3):430-7. PubMed ID: 11104615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.